Alnylam Pharmaceuticals
ALNY
ALNY
645 hedge funds and large institutions have $43B invested in Alnylam Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 96 funds opening new positions, 257 increasing their positions, 214 reducing their positions, and 62 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
3.41% more ownership
Funds ownership: 97.81% → 101.22% (+3.4%)
8% less call options, than puts
Call options by funds: $188M | Put options by funds: $203M
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Holders
645
Holding in Top 10
9
Calls
$188M
Puts
$203M
Top Buyers
| 1 | +$195M | |
| 2 | +$195M | |
| 3 | +$179M | |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$172M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$162M |
Top Sellers
| 1 | -$208M | |
| 2 | -$204M | |
| 3 | -$175M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$117M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$89.2M |
